Consensus Dr. Reddy's Laboratories Limited NYSE

Stocks

RDY

US2561352038

Pharmaceuticals

Market Closed - NYSE Other stock markets 16:00:02 2026-08-10 EDT			5-day change	1st Jan Change
12.15 ^USD	-0.57%		+0.66%	-13.46%

08-10	Asian Equities Traded in the US as American Depositary Receipts Decline in Monday Trading	MT
08-06	Asian Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT

Evolution of the Average Target: Dr. Reddy's Laboratories Limited

Evolution of the Target Price: Dr. Reddy's Laboratories Limited

Changes in Analyst Recommendations: Dr. Reddy's Laboratories Limited

6fa0da7a3fc72dac0635af073c.mVihOFgGexY31F8-sRILTZAGdHw9CwxOVSpNPe4bWTs.-yn7cBVcMXBxlQ1p_XRhPPZ2Nw1JSTkCbAcYR4x6NAz8KvtWN0gWeQG9MA~c78699b3d3edecc02439bfd27dcb9c80

Analysts' recommendations: Dr. Reddy's Laboratories Limited

07-10	Elara Securities India Downgrades Dr. Reddy's Laboratories to Reduce From Accumulate; Price Target is INR1,283	MT
06-22	Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,740 From INR1,600, Keeps at Buy	MT
01-23	YES Research Upgrades Dr. Reddy's Laboratories to Add from Reduce, Price Target is INR1,340	MT
01-23	Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,600 From INR1,580, Keeps at Buy	MT
01-22	ICICI Securities Upgrades Dr. Reddy's Laboratories to Add from Hold, Price Target is INR1,300	MT
01-22	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,040 from INR1,100, Keeps at Underperform	MT
25-10-30	Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,580 From INR1,650, Keeps at Buy	MT
25-10-27	Choice Equity Upgrades Dr. Reddy's Laboratories to Add from Reduce; Price Target is INR1,380	MT
25-10-27	Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,650 From INR1,660, Keeps at Buy	MT
25-10-27	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,130 From INR1,100, Keeps at Underperform	MT
25-10-13	BNP Paribas Exane Initiates Dr. Reddy's Laboratories at Neutral With $13.18 Price Target	MT
25-07-25	Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,660 From INR1,575, Keeps at Buy	MT
25-07-24	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,100 From INR1,010, Keeps at Underperform	MT
25-05-12	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,010 from INR1,170, Keeps at Underperform	MT
25-01-27	Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,575 From INR1,500, Keeps at Buy	MT
25-01-24	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,170 From INR1,210, Keeps at Underperform	MT
24-12-20	Nomura Upgrades Dr. Reddy's Laboratories to Buy From Neutral, Cuts Price Target to 1,500 Indian Rupees From 6,499 Indian Rupees	MT
24-11-06	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,130 From INR1,120, Keeps at Underperform	MT
24-07-29	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR5,600 From INR5,010, Keeps at Underperform	MT
24-05-08	Jefferies Adjusts Dr. Reddy’s Laboratories’ Price Target to INR5,010 From INR5,040, Keeps at Underperform	MT
24-01-29	Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $80 From $75, Keeps Overweight Rating	MT
23-10-30	Jefferies Adjusts Dr. Reddy’s Laboratories’ Price Target to INR6,250 From INR6,330, Keeps at Buy	MT
23-07-27	Jefferies Adjusts Dr. Reddy Laboratories’ to INR6,300 From INR5,600, Keeps at Buy	MT
23-06-01	Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $70 From $67, Maintains Overweight Rating	MT
23-01-30	Nomura Adjusts Dr Reddy's Laboratories' Price Target to INR5,161 From INR5,552, Keeps at Buy	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+4.92%
	JOHNSON & JOHNSON					+4.08%
	ABBVIE INC.					+10.64%
	ROCHE HOLDING AG					-0.75%
	NOVARTIS AG					-1.64%
	ASTRAZENECA PLC					+30.55%
	AMGEN INC.					-8.54%
	NOVO NORDISK A/S					+2.68%
	GILEAD SCIENCES, INC.					+18.3%
	Average					+6.69%
	Weighted average by Cap.					+5.76%